Reviewing Surface Oncology Inc. (SURF)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – FinanceMercury

Surface Oncology Inc. (NASDAQ:SURF) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Surface Oncology Inc. and Brainstorm Cell Therapeutics Inc.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Liquidity

The Current Ratio and a Quick Ratio of Surface Oncology Inc. are 11.3 and 11.3. Competitively, Brainstorm Cell Therapeutics Inc. has 1 and 1 for Current and Quick Ratio. Surface Oncology Inc.s better ability to pay short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for Surface Oncology Inc. and Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. on the other hand boasts of a $9 consensus price target and a 138.73% potential upside.

Institutional and Insider Ownership

The shares of both Surface Oncology Inc. and Brainstorm Cell Therapeutics Inc. are owned by institutional investors at 71.6% and 11.4% respectively. 0.2% are Surface Oncology Inc.s share owned by insiders. Insiders Comparatively, owned 0.6% of Brainstorm Cell Therapeutics Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Surface Oncology Inc. has -47.88% weaker performance while Brainstorm Cell Therapeutics Inc. has 12.96% stronger performance.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Continued here:
Reviewing Surface Oncology Inc. (SURF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury